Core Viewpoint - Meili Tianyuan Medical Health (02373) announced a share buyback plan, intending to repurchase 70,000 shares at a cost of HKD 2.2095 million [1] Company Summary - The company plans to execute the buyback on October 20, 2025 [1]

Core Viewpoint - The company announced a strategic acquisition of 100% equity in Shanghai Siyuanli Industrial Co., Ltd. for 1.25 billion RMB, further solidifying its leading position in China's beauty service industry, which is projected to grow significantly in the coming years [1][2]. Group 1: Acquisition Details - The acquisition of Siyuanli, a high-end beauty service brand established in 1996, positions the company among the top three beauty service brands in China, with Siyuanli projected to generate 850 million RMB in revenue and 81 million RMB in net profit in 2024 [1]. - Following the acquisition, the company will hold a market share among the top three brands in the beauty industry, enhancing its competitive advantage, especially in first-tier cities, which contribute nearly 20% of the national beauty service market share [1]. Group 2: Performance Impact - The acquisition is expected to significantly increase the company's performance, with Siyuanli's approximately 60,000 active members being integrated into the group's membership system, leading to a projected 44% year-on-year growth in active members [2]. - The company has a strong track record of improving profitability through mergers and acquisitions, as evidenced by the net profit margin increase of the recently acquired brand Naieryi from 6.5% in 2023 to 10.4% in the first half of 2025 [2]. Group 3: Business Growth - The company's recent anniversary celebration activities showed robust growth, with total rights revenue exceeding 510 million RMB, a year-on-year increase of 13.7%, and net consumption reaching 400 million RMB, up 9.3% year-on-year [2]. - Various business segments, including beauty and health, medical beauty, and healthcare, demonstrated steady growth, with net consumption and customer traffic increasing across the board [2]. Group 4: Profit Forecast - The company has adjusted its profit forecast, expecting net profits of 330 million RMB, 370 million RMB, and 420 million RMB for 2025 to 2027, representing year-on-year growth rates of 43%, 14%, and 11% respectively [3]. - The projected price-to-earnings ratios for 2025, 2026, and 2027 are 21X, 19X, and 17X, respectively, maintaining a "buy" rating based on the anticipated performance growth [3].

Group 1 - The company repurchased 70,000 shares on October 20, 2025, for a total transaction amount of approximately HKD 2.209 million, with an average price of HKD 31.56 per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 210,000 shares, with a total consideration of approximately HKD 6.858 million [1]

格隆汇10月20日丨美丽田园医疗健康(02373.HK)公告，10月20日耗资221万港元回购7万股。 ...

Group 1 - The company, 美丽田园医疗健康 (02373), announced a share buyback plan on October 20, 2025, involving an expenditure of HKD 2.2095 million to repurchase 70,000 shares [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) announced a share buyback plan, intending to repurchase 70,000 shares at a cost of HKD 2.2095 million, scheduled for October 20, 2025 [1] Company Summary - The company is engaging in a share repurchase, indicating a potential strategy to enhance shareholder value [1] - The total expenditure for the buyback is set at HKD 2.2095 million, reflecting the company's commitment to returning capital to shareholders [1] - The buyback involves 70,000 shares, which may influence the stock's liquidity and market perception [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 美麗田園醫療健康產業有限公司 呈交日期： 2025年10月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02373 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（ ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Beauty Farm Medical and Health Industry Inc. 美麗田園醫療健康產業有限公司 * （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2373） 自願公告 李陽 本公告由美麗田園醫療健康產業有限公司（「本公司」，連同其附屬公司統稱「本集 團」）自願刊發。 本公司欣然公佈，本公司於2025年10月20日於市場購回70,000股本公司股份，總交 易金額約2,209,470港元，交易平均價約每股31.56港元。自2025年10月15日至本公 告日期止期間，本公司已購回共210,000股股份，總對價約6,858,180港元。 本公司董事（「董事」）會（「董事會」）認為，目前的股份成交價並不反映股份的內在價 值和本公司的實際業務前景。董事會相信，股份購回體現了管理層對企業長期價值 的堅定信心，有利於提升本集團資本市場價值及股東回報能力。本次股份購 ...

Investment Rating - The report maintains a rating of "Add" for the company [6] Core Viewpoints - The company has strategically acquired 100% of Shanghai Siyuanli Industrial Co., Ltd. for 1.25 billion RMB, further solidifying its position as a leader in the high-end beauty sector [1] - Following the acquisition, the company will hold the top three brands in China's beauty industry, enhancing its competitive advantage, especially in first-tier cities [5] - The acquisition is expected to significantly boost performance, with approximately 60,000 active members from Siyuanli being integrated into the company's membership system, leading to a 44% year-on-year increase in active members [5] - The company has a strong track record in merger integration, which has previously improved profitability, and this trend is expected to continue post-acquisition [5] - Recent business activities have shown robust growth, with a notable increase in revenue and customer traffic during the company's anniversary celebration [5] Financial Projections - The company forecasts net profits of 330 million, 370 million, and 420 million RMB for 2025, 2026, and 2027, representing year-on-year growth rates of 43%, 14%, and 11% respectively [6] - Revenue projections for 2025, 2026, and 2027 are set at 2.991 billion, 3.290 billion, and 3.555 billion RMB, with growth rates of 16.29%, 10.00%, and 8.06% respectively [7]

Summary of Key Points Core Viewpoint - On October 17, 42 Hong Kong-listed companies conducted share buybacks, totaling 46.36 million shares and an aggregate amount of HKD 621 million [1][2]. Company-Specific Summaries - **Xiaomi Group-W**: - Repurchased 10.70 million shares for HKD 494 million, with a highest price of HKD 46.760 and a lowest price of HKD 45.900. The total buyback amount for the year reached HKD 1.537 billion [1][2]. - **Sihuan Pharmaceutical**: - Repurchased 15 million shares for HKD 21.76 million, with a highest price of HKD 1.470 and a lowest price of HKD 1.430. The total buyback amount for the year reached HKD 143.32 million [1][2]. - **Mengniu Dairy**: - Repurchased 1.20 million shares for HKD 16.97 million, with a highest price of HKD 14.250 and a lowest price of HKD 14.070. The total buyback amount for the year reached HKD 433.54 million [1][2]. - **AAC Technologies**: - Repurchased 300,000 shares for HKD 11.60 million, with a highest price of HKD 38.800 and a lowest price of HKD 38.480. The total buyback amount for the year reached HKD 84.64 million [1][2]. - **Vitasoy International**: - Repurchased 1.02 million shares for HKD 8.20 million, with a highest price of HKD 8.040 and a lowest price of HKD 8.020. The total buyback amount for the year reached HKD 27.54 million [1][2]. Overall Market Activity - The highest buyback amount on October 17 was from Xiaomi Group-W at HKD 494 million, followed by Sihuan Pharmaceutical at HKD 21.76 million. Other notable companies included Mengniu Dairy and AAC Technologies [1][2]. - In terms of share quantity, Sihuan Pharmaceutical led with 15 million shares repurchased, followed by Xiaomi Group-W with 10.70 million shares and Anton Oilfield Services with 4.49 million shares [1][2].